Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Artiva, a Spin-out from Korea’s GC Cell, Raises $167 Million in US IPO

publication date: Jul 22, 2024

San Diego’s Artiva Bio raised $167 million in a NASDAQ IPO to support clinical trials of its cell therapy portfolio. Artiva was spun out of South Korea’s GC Cell and has global rights (ex-Asia, Australia and New Zeeland) to GC Cell’s portfolio. The IPO was priced at $12 per share, lower than the expected $14-$16 range, but Artiva upped the number of shares in the IPO. Founded in 2019, Artiva develops natural killer (NK) cells that are developed from cord blood, making them allogeneic, unlike CAR-T therapies that are derived from a patient’s own cells. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here